AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

Uncover how chicken processors are transforming the protein market with smart technologies and consumer-focused innovations ...

Trackonomy reports cargo theft is a rising issue in supply chains, costing billions while advanced technology helps combat ...

South African health crisis no one’s talking about According to a 2023 UNEP report, the world produces 430 million tonnes of plastic annually, and 280 million tonnes of it become waste after just one ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...